All In Biotech

Drug Trial Radar · NCT05972954

OMT-28 in Patients With Primary Mitochondrial Disease (PMD) (PMD-OPTION)

A Phase 2a Safety, Tolerability, and Pharmacodynamic Study of OMT-28 in PMD Patients With Myopathy and/or Cardiomyopathy and Inflammation (PMD-OPTION)

Last checked: Nov 19, 2026Latest source record: Jan 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

28

Actual

Start

May 22, 2023

Primary completion

May 14, 2025

Study completion Jul 30, 2025

Sponsor

Lead sponsor
Omeicos Therapeutics GmbHIndustry
Sponsor type
Industry
First posted
Aug 2, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 60 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this clinical trial is to learn about the treatment effects of the investigational new drug OMT-28 in patients with Primary Mitochondrial Disease. The main question\[s\] it aims to answer are: * Is OMT-28 safe and well tolerated in this patient population? * Does OMT-28 reduce Growth Differentiation Factor 15 (GDF-15) and other relevant blood markers of mitochondrial dysfunction and inflammation? * Does OMT-28 improve symptoms of the disease, e.g. fatigue or exercise intolerance? Participants will be asked to participate in 6 study visits at an experienced clinical center, including physical examinations and exercise tests, and take the study medication regularly once per day according to the protocol. Researchers will compare for every participant the results after 3 months and 6 months of treatment with a preceding 3 month period of standard care treatment to investigate the effects of OMT-28 on clinical parameters and a number of blood parameters.

Conditions

  • Primary Mitochondrial Disease

Interventions

  • OMT-28Drug

    once daily

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Responder rateTime frame: 12 weeks treatment vs. 12 weeks baseline
  2. Number of Treatment Emergent Adverse Events (TEAE)Time frame: up to 28 weeks

Locations

9 sites in 3 countries. Site status is shown where the registry gives one.

  • Universitätsklinikum Bonn, Sektion Neuromuskuläre Erkrankungen, Klinik und Poliklinik für Neurologie, Venusberg-Campus 1, Gebäude 80, NPP

    Bonn, Germany

  • Medizinisch Fakultät der Martin-Luther-Universität Halle-Wittenberg Universitätsklinik und Poliklinik für Neurologie Universitätsklinikum , Ernst-Grube-Str. 40

    Halle, Germany

  • Friedrich-Baur-Institut an der Neurologischen Klinik und Poliklinik, Klinikum der Universität München, Ludwig-Maximilians-Universität (LMU Klinikum), Ziemssenstr. 1a

    Munich, Germany

  • IRCCS Institute of Neurological Science of Bologna, University of Bologna, Department of Biomedical and Neuromotor Science (DIBINEM), Ospedale Bellaria Via Altura, 3

    Bologna, Italy

  • U.O.C. di Neurologia e Malattie Neuromuscolari

    Messina, Italy

  • IRCCS Istituto Neurologico Carlo Besta, SC Servizio Di Medicina Di Laboratorio - Genetica Medica E Neurogenetica, Via Celoria 11

    Milan, Italy

  • Azienda Ospedaliero Universitaria Pisana, P.O. Santa Chiara, U.O. Neurologia, Edificio 13, Via Roma 67

    Pisa, Italy

  • UOC di neurofisiopatologia

    Roma, Italy

  • Radboud University Nijmegen Medical Centre

    Nijmegen, Gelderland, Netherlands

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.